Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD7762 + irinotecan
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AZD7762 + irinotecan is a combination of a **selective checkpoint kinase inhibitor** (AZD7762) and a **topoisomerase I inhibitor** (irinotecan) developed for the treatment of advanced solid tumors. **AZD7762** is a potent, selective ATP-competitive inhibitor of Chk1 (checkpoint kinase 1), which disrupts cell cycle arrest in response to DNA damage, thereby potentiating the cytotoxicity of DNA-damaging agents. Irinotecan inhibits topoisomerase I, preventing DNA re-ligation and causing cell death. Preclinical studies have shown that AZD7762 enhances the effect of irinotecan and its active metabolite SN-38. This combination was investigated in a Phase I open-label, dose-escalation clinical trial in patients with advanced solid malignancies, administered via intravenous infusion. The trial was sponsored and developed by AstraZeneca.
- Brand names
- Campto
- Other names
- irinotecan hydrochloride
02
Targets
CHEK2 (Checkpoint kinase 2)TOP1 (DNA Topoisomerase I)CHEK1 (Checkpoint kinase 1)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on AZD7762 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD7762 + irinotecan.